Abstract
Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set the scene covering the history of CPI therapy to date and outlining the likely future developments.
Keywords:
cancer; drug development; immunotherapy; toxicity.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents, Immunological / adverse effects*
-
Antineoplastic Agents, Immunological / therapeutic use
-
CTLA-4 Antigen / antagonists & inhibitors
-
Humans
-
Immunologic Factors / adverse effects*
-
Immunologic Factors / therapeutic use
-
Immunotherapy / adverse effects*
-
Immunotherapy / methods
-
Immunotherapy / trends
-
Ipilimumab / adverse effects
-
Ipilimumab / therapeutic use
-
Melanoma / drug therapy
-
Neoplasms / drug therapy*
-
Prognosis
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Substances
-
Antineoplastic Agents, Immunological
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Immunologic Factors
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor